{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-26-001349","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2026-08-06T12:15:17+00:00","discovered_at":"2026-08-06T12:20:00.284968+00:00","generated_at":"2026-08-06T12:20:13.555105+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vivani Medical completes dosing of all 20 participants in Phase 1 trial of NPM-139 semaglutide implant","bullets":["First 10 participants dosed July 29, 2026; remaining 10 dosed one week later; all insertions successful.","Top-line data from the 20-participant SLIM-1 trial expected in November 2026.","Trial includes low-dose NPM-139 and Wegovy comparator to assess safety, tolerability, PK, and weight change.","Preclinical studies demonstrated sustainable 20% weight reduction in animal models.","July 2026 agreement with Novo Nordisk to evaluate NPM-139 and NanoPortal implant technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-26-001349","json":"https://secwatch.observer/filing/0001753926-26-001349.json","markdown":"https://secwatch.observer/filing/0001753926-26-001349.md","text":"https://secwatch.observer/filing/0001753926-26-001349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/0001753926-26-001349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001349/vani-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T12:20:13.555105+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}